TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

QUAD PHARMS

OncologyDermatologyInfectious Disease
Pharma

QUAD PHARMS is a pharmaceutical company focused on Oncology, Dermatology, Infectious Disease. Key products include GLYCOPYRROLATE.

-
Since
58
Drugs
-
Trials
331
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

DOXYCYCLINE HYCLATE 2026-02-19
FLUOROURACIL 2026-02-10
Labeling
GLYCOPYRROLATE 2026-02-10
Labeling
FLUOROURACIL 2026-02-10
Labeling
GLYCOPYRROLATE 2026-02-06
Labeling
DOXYCYCLINE HYCLATE 2026-02-06
Labeling
DOXYCYCLINE HYCLATE 2026-02-06
Labeling
FLUOROURACIL 2026-02-05
Labeling
FLUOROURACIL 2026-02-05
Labeling
FLUOROURACIL 2026-02-05
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 22%
2 drugs
Dermatology 22%
2 drugs
Infectious Disease 22%
2 drugs
Gastroenterology 22%
2 drugs
Immunology 11%
1 drugs

Pipeline Strength Pro

Loading...

Competitors Pro

Pfizer big-pharma
Oncology, Infectious Disease, Dermatology, Immunology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology, Infectious Disease
COSETTE other
Dermatology, Infectious Disease, Immunology, Oncology
Merck big-pharma
Oncology, Infectious Disease, Immunology
Baxter specialty
Infectious Disease, Oncology, Dermatology